Shares of Imperva Inc (NASDAQ:IMPV) have earned an average recommendation of “Hold” from the eighteen ratings firms that are presently covering the stock, MarketBeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $57.06.
Several equities analysts have commented on IMPV shares. JPMorgan Chase & Co. lifted their target price on shares of Imperva from $45.00 to $48.00 and gave the stock an “underweight” rating in a research report on Friday, July 27th. Zacks Investment Research raised shares of Imperva from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Royal Bank of Canada dropped their target price on shares of Imperva to $56.00 and set an “outperform” rating on the stock in a research report on Thursday. They noted that the move was a valuation call. Evercore ISI reissued a “buy” rating and set a $56.00 target price on shares of Imperva in a research report on Friday, July 27th. Finally, Macquarie cut shares of Imperva from an “outperform” rating to a “neutral” rating and set a $55.00 target price on the stock. in a research report on Thursday.
Several hedge funds have recently modified their holdings of IMPV. Russell Investments Group Ltd. increased its stake in shares of Imperva by 276.2% during the 1st quarter. Russell Investments Group Ltd. now owns 2,588 shares of the software maker’s stock worth $112,000 after purchasing an additional 1,900 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Imperva by 99.4% during the 1st quarter. Royal Bank of Canada now owns 2,794 shares of the software maker’s stock worth $122,000 after purchasing an additional 1,393 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Imperva during the 2nd quarter worth approximately $203,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Imperva during the 1st quarter worth approximately $205,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Imperva during the 2nd quarter worth approximately $222,000. Institutional investors own 99.99% of the company’s stock.
Imperva stock opened at $55.36 on Wednesday. Imperva has a 52 week low of $37.17 and a 52 week high of $57.65. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -197.71 and a beta of 1.72.
Imperva (NASDAQ:IMPV) last posted its earnings results on Thursday, July 26th. The software maker reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. Imperva had a negative net margin of 8.59% and a negative return on equity of 6.92%. The firm had revenue of $84.80 million for the quarter, compared to analysts’ expectations of $87.22 million. During the same quarter last year, the firm earned $0.24 EPS. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. On average, sell-side analysts forecast that Imperva will post -1.15 earnings per share for the current year.
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.